New generation approaches revive BET protein inhibitors in solid tumors
Researchers are developing a new generation of BET protein inhibitors to treat solid tumors after first-generation drugs failed due to toxicity and resistance. These advancements aim to overcome previous clinical limitations by targeting oncogenic transcription more effectively.
Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member New generation approaches revive BET protein inhibitors in solid tumors Download PDF Copy Add News Medical on Google as a preferred source Xia & He Publishing Inc. Jul 11 2026 Reviewed BET proteins, especially BRD4, drive oncogenic transcription in solid tumors. First‑generation inhibitors (JQ1, molibresib, birabresib) showed preclinical promise but failed clinically due to modest efficacy, dose‑limiting thrombocytopenia, and resistance (isoform switching, compensatory PI3K/AKT/WNT signaling). Responses are best in NUT carcinoma and castration‑resistant prostate cancer. Next‑generation approaches-BD2‑selective inhibitors, PROTAC degraders, and rational combinations with PARP inhibitors, AR antagonists, or immune checkpoint blockade-offer renewed hope. This review summarises the current landscape and future directions for BET targeting in solid oncology.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in